Miroslav Ferenčík

Miroslav Ferenčík

Auto-generated profile, based on publicly available information

Miroslav Ferenčík

Department of Algesiology of Slovak Medical University, F.D. Roosevelt University Hospital with Policlinic Banska Bystrica, Banska Bystrica, Slovakia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2025 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
IMIgor Martuliak
Igor Martuliak
ĽCĽuboš Chvála
Ľuboš Chvála
MFMiroslav Ferenčík
Miroslav Ferenčík
VFVratislav Fabián
Vratislav Fabián
MSMatěj Slovák
Matěj Slovák
Introduction Rebox therapy is a form of noninvasive transcutaneous electrotherapy, which delivers microcurrent kilohertz-frequency pulses in multiple points over the target area. Despite decades of use in pain management, clinical evidence supporting Rebox remains inconclusive, with a lack of rigorous sham-controlled trials. This study aimed to evaluate its analgesic effect in a single-center, randomized, double-blind, sham-controlled crossover trial. Methods The study included consecutive patients with non-cancer nociceptive pain with average pain intensity ≥ 4 on a numerical rating scale (NRS), and pain duration of 2–12 weeks (de novo or acutely exacerbated chronic pain). Patients were randomized (1:1) into two arms based on the sequence of stimulation periods. Each period consisted of eight sessions of either Rebox or sham treatment, administered every other working day, with a 1-week washout period. The primary outcome was the difference in the reduction of pain intensity (average and worst pain in the last 24 h) following active versus sham stimulation. Results Seventy-one patients completed the study, with musculoskeletal back pain being the most common indication (n = 60). Compared to the sham, Rebox significantly reduced both average pain (NRS difference: 2.2, 95% CI 0.8–3.6, Cohen’s d = 0.75, p = 0.002) and worst pain (NRS difference: 2.3, 95% CI 1.2–3.5, Cohen’s d = 0.91, p < 0.001). A significant placebo analgesic effect was observed only in the sham-first arm. The treatment was well tolerated, with only minor and transient side effects. Conclusion Rebox demonstrated a significant analgesic effect compared to the sham. The treatment was safe and well tolerated. These findings support integrating Rebox into clinical pain management, warranting further investigation in larger trials.